The 10-second takeaway
For the quarter ended Dec. 30 (Q4), STAAR Surgical missed estimates on revenues and crushed expectations on earnings per share.
Compared to the prior-year quarter, revenue grew and GAAP earnings per share improved to zero.
Margins grew across the board.
STAAR Surgical booked revenue of $16.4 million. The five analysts polled by S&P Capital IQ expected to see net sales of $16.7 million on the same basis. GAAP reported sales were 14% higher than the prior-year quarter's $14.4 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Non-GAAP EPS came in at $0.03. The five earnings estimates compiled by S&P Capital IQ predicted $0.02 per share on the same basis. GAAP EPS contracted to zero from the prior-year quarter's -$0.02.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 69.8%, 400 basis points better than the prior-year quarter. Operating margin was 4.1%, 780 basis points better than the prior-year quarter. Net margin was 0.7%, 550 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $17.1 million. On the bottom line, the average EPS estimate is $0.03.
Next year's average estimate for revenue is $73.0 million. The average EPS estimate is $0.15.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 87 members rating the stock outperform and 13 members rating it underperform. Among 27 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 20 give STAAR Surgical a green thumbs-up, and seven give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on STAAR Surgical is buy, with an average price target of $10.17.
The health-care investing landscape is littered with also-rans and a few major winners. Is STAAR Surgical performing well enough for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will deliver amazing returns during the next few years. Click here for instant access to this free report.
- Add STAAR Surgical to My Watchlist.